Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CellFE
AddedFeb 17, 2024
UpdatedJun 18, 2026
CellFE

CellFE

Series A

CellFE: A cell engineering startup innovating efficient gene-editing delivery via microfluidic devices.

HQ
Alameda, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees

CellFE is a cell engineering startup focused on developing microfluidic-based devices to deliver gene-editing molecules into human cells. Their core mission is to enhance the efficiency and precision of gene-editing delivery, thereby advancing cellular therapies and research. The company targets the biotechnology and healthcare markets, aiming to revolutionize gene-editing techniques.

CellFE has made significant strides in creating a microfluidic device that optimizes the delivery of gene-editing molecules. Their innovative approach has the potential to impact various applications in medicine and research, contributing to advancements in gene therapy and personalized medicine.

CellFE - Similar Companies

ExpressCells logo

ExpressCells

GenEdit logo

GenEdit

genedit.com

CytoRecovery logo

CytoRecovery

cytorecovery.com

CytoMag logo

CytoMag

Indee Labs logo

Indee Labs

indeelabs.com

GeneTether logo

GeneTether

genetether.com

Kytopen logo

Kytopen

kytopen.com

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Cellino logo

Cellino

cellinobio.com

OpenCell Technologies logo

OpenCell Technologies

Celldom logo

Celldom

celldom.com

CellChorus logo

CellChorus

cellchorus.com

Cellibre logo

Cellibre

cellibre.com

Encellin logo

Encellin

encellin.com

CyteQuest logo

CyteQuest

cytequest.com

CellFE - Quick Facts

Who are CellFE's competitors?

Companies similar to CellFE include ExpressCells, GenEdit, CytoRecovery and CytoMag.

When was CellFE founded?

CellFE was founded in 2018.

Where is CellFE's headquarters located?

CellFE's headquarters is located in Alameda, CA, US.

When was CellFE's last funding round?

CellFE's most recent funding round was for $22M (USD) in September 2023.

How much has CellFE raised to-date?

As of Sep 27, 2023, CellFE has raised a total of $26.8M (USD).

How many employees does CellFE have?

CellFE has 35 employees as of Feb 4, 2024.

CellFE - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • Microfluidics
Geographic Exposure
  • Global
Revenue
  • Recurring
Main Product
  • Cell Therapies
  • Gene Editing
Tags
  • Consulting
  • Hardware
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software